Protalix BioTherapeutics (PLX) Change in Cash (2010 - 2026)

Protalix BioTherapeutics' Change in Cash history runs 17 years deep, the most recent figure standing at $26.3 million for Q1 2026.

• On a quarterly basis, Change in Cash rose 8815.56% year-over-year to $26.3 million in Q1 2026; TTM through Mar 2026 was $21.5 million, a 377.94% increase from a year earlier, with the FY2025 full-year figure at -$5.1 million, down 31.13% from the prior year.
• Change in Cash advanced to $26.3 million in Q1 2026 per PLX's latest filing, from $1.0 million in the prior quarter.
• Across five years, Change in Cash topped out at $26.3 million in Q1 2026 and bottomed at -$27.8 million in Q3 2023.
• The 5-year median for Change in Cash is -$302000.0 (2025), against an average of $118588.2.
• Across the five-year window, Change in Cash tumbled 1511.95% in 2022 and surged 8815.56% in 2026, its largest moves.
• Year by year, Change in Cash stood at $6.4 million in 2022, then tumbled by 49.52% to $3.2 million in 2023, then sank by 337.1% to -$7.6 million in 2024, then surged by 113.51% to $1.0 million in 2025, then surged by 2448.02% to $26.3 million in 2026.
• Per Business Quant, the three latest PLX Change in Cash figures stand at $26.3 million (Q1 2026), $1.0 million (Q4 2025), and -$4.2 million (Q3 2025).